Alice Elizabeth McGee

Alice Elizabeth McGee

Auto-generated profile, based on publicly available information

Alice Elizabeth McGee

Flo Health UK Limited

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Open access
AMA.E. McGee
A.E. McGee
TAT. Alibegashvili
T. Alibegashvili
KEK. Elfgren
K. Elfgren
BFB. Frey
B. Frey
MGM. Grigore
M. Grigore
MCM.E. Cruickshank
M.E. Cruickshank
Following the publication of the European consensus statement on standards for essential colposcopy in 2020, the need for standards relating to more complex and challenging colposcopy practice was recognised. These standards relate to colposcopy undertaken in patients identified through cervical screening and tertiary referrals from colposcopists who undertake standard colposcopy only. This set of recommendations provides a review of the current literature and agreement on care for recognised complex cases. With good uptake of human papillomavirus (HPV) immunisation, we anticipate a marked reduction in cervical disease over the next decade. Still, the expert colposcopist will continue to be vital in managing complex cases, including previous cervical intraepithelial neoplasia (CIN)/complex screening histories and multi-zonal disease. To provide expert guidance on complex colposcopy cases through published evidence and expert consensus. Members of the EFC and ESGO formed a working group to identify topics considered to be the remit of the expert rather than the standard colposcopy service. These were presented at the EFC satellite meeting, Helsinki 2021, for broader discussion and finalisation of the topics. The agreed standards included colposcopy in pregnancy and post-menopause, investigation and management of glandular abnormalities, persistent high-risk HPV+ with normal/low-grade cytology, colposcopy management of type 3 transformation zones (TZ), high-grade cytology and normal colposcopy, colposcopy adjuncts, follow-up after treatment with CIN next to TZ margins and follow-up after treatment with CIN with persistent HPV+, and more. These standards are under review to create a final paper of consensus standards for dissemination to all EFC and ESGO members.

2 October 2024 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Open access
AMA.E. McGee
A.E. McGee
SHS. Hawco
S. Hawco
SBS. Bhattacharya
S. Bhattacharya
SHS.J.B. Hanley
S.J.B. Hanley
MCM.E. Cruickshank
M.E. Cruickshank
In 2021, the World Health Organisation (WHO) updated its guidelines for cervical screening from cytology testing to primary high-risk human papillomavirus (HR-HPV) testing. This change in testing has effectively led to a 'new disease' as women are now aware of having a virus that induces changes that can cause cancer, which they would have been unaware of previously. While current management involves a 'watch and wait' approach and no active treatment, the anxiety associated with having HR-HPV may prompt some women to seek 'treatments' outside the screening programme. ● to identify potential treatment options available for women with persistent HR-HPV and/or low-grade cervical intraepithelial neoplasia (CIN), i.e. ≤CIN 1. ● to determine the clinical effectiveness of these treatments, namely by: ◦ HR-HPV clearance rate, and/or: ◦ CIN regression. We searched MEDLINE, PubMed, EMBASE, Web of Science and the Cochrane Library. We included cohort studies and randomised controlled trials (RCTs) only. Records (n = 2135) were screened in Rayyan by two independent reviewers. Quality assessment was conducted using the ROBINS-I tool and the ROB-2 tool. 12 studies (four cohort studies and eight RCTs) were included: six oral medications, two topical medications, one vaccination, and three non-surgical device treatments. Meta-analysis revealed that some therapeutic interventions, including vaginal gels, photodynamic therapy, and some oral medications, may lead to earlier resolution of persistent HR-HPV and regression of low-grade CIN when compared with natural clearance. This review can better inform discussions with HR-HPV+ women and answer their questions about alternatives to surveillance.

4 March 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
AMAlice Elizabeth McGee
Alice Elizabeth McGee
FCFergus Cooper
Fergus Cooper
SMSangeeta Kapur Maini
Sangeeta Kapur Maini
VVVamsidhar Vallamkondu
Vamsidhar Vallamkondu
Pott’s puffy tumour (PPT) is a rarely seen, but highly important, complication of frontal sinusitis. Early recognition followed by prompt imaging and treatment of this condition are essential to improve patient outcomes and prevent complications. This case report describes an atypical presentation of radiologically confirmed PPT in a boy who presented with a 2.5-week history of progressive frontal headache and midline frontal swelling. Flexible nasendoscopy revealed no acute findings. Prompt CT imaging confirmed the diagnosis and early surgical intervention via endoscopic approach with aggressive antibiotic therapy led to good recovery. This case highlights the need to remember PPT in assessing any child or adolescent with a new forehead swelling, with or without sinusitis symptoms. If there is strong clinical suspicion, further imaging should not be delayed. Surgical intervention should be performed as early as possible to prevent intracranial complications; antibiotics alone are not sufficient.

1 February 2026 in Digital Health
Verified
Journal Article
Open access
AMAlice E McGee
Alice E McGee
GPGuy Parsons
Guy Parsons
LZLiudmila Zhaunova
Liudmila Zhaunova
APAlison Paul
Alison Paul
AKAliaksandr Kazlou
Aliaksandr Kazlou
AMAndrás Meczner
András Meczner
Background: Large language models (LLMs) offer opportunities for sexual health education, but integrating them into digital products presents clinical challenges and risks, particularly regarding clinical safety and monitoring at scale. This study designed and evaluated a safety-focused framework for an LLM-based sexual well-being chatbot in a mobile application. Methods: We conducted a methods-focused feasibility study comprising a multi-stage development and evaluation of the chatbot. We used an interdisciplinary, medically led three-phase development process, including a five-stage evaluation framework combining synthetic test cases, clinician-led vulnerability testing and controlled release to real users to assess clinical accuracy and safety. Results: The chatbot met predefined precision and recall thresholds in synthetic testing. Clinically inaccurate responses remained below 2% across clinician review stages, with no high-severity unsafe responses. In a controlled release, 5195 real user interactions were reviewed. Clinically inaccurate responses occurred in 0.90% (47/5195) of dialogues, with unsafe responses within severity thresholds. Conclusion: This study demonstrates the feasibility of a structured framework for developing and evaluating LLM-based sexual health chatbots with clinical safety oversight. This approach helps to address gaps in safety reporting and could be adapted for other sensitive clinical domains.

17 September 2024 in JMIR Preprints
Verified
Preprint
Open access
LTLaura Joo Peng Tan
Laura Joo Peng Tan
MNMoira Newiss
Moira Newiss
AMAlice McGee
Alice McGee
GMGuy Martin
Guy Martin
JNJean Nehme
Jean Nehme
BACKGROUND Long COVID is characterised by an array of physical and psychological symptoms that can be debilitating. Given the enormous number of individuals affected by long COVID, it presents a significant, and poorly understood emerging long-term medical and socioeconomic challenge. As such, there is a pressing need to develop and test new holistic and efficient approaches to whole-person treatment and rehabilitation at scale for patients with long COVID. OBJECTIVE To evaluate the effectiveness of a new human-centred, digital-first health platform - Avid - for the management of long COVID by examining its impact on participants quality of life scores and symptom severity in the short-term, and the platform’s usability and acceptability for end-users. METHODS 37 participants (35 female, mean age 46.5 years, 8.1% previously hospitalised with acute COVID) with long Covid were recruited into the Avid program. Avid is a human-centred, digital-first platform that delivers a 6-week program providing structured, personalised health coaching and tailored digital content aligned to specific weekly goals. The approach facilitates a standardised approach through evidenced-based treatment strategies, whilst simultaneously supporting personalised, adaptable care at scale. A quasi-experimental single arm pre-post intervention design was employed to evaluate the platform. The primary outcome measures were C19-YRSm and EQ5D-5L quality of life scores. Usability and acceptability of the program for participants was examined through Net Promoter Scores (NPS) and qualitative semi-structured interviews. RESULTS The Avid program led to significant and sustained improvements in C19-YRSm scores at week 6 (5.57 (SD 1.79) vs. 3.95 (SD 1.35), p=0.0001, mean improvement 41.0%); week 10 (5.07 (SD1.78) vs. 3.93 (1.18), p=0.0003, mean improvement 29.0%); and week 22 (5.08 (SD 1.68) vs. 3.88 (SD 1.13), p=0.0001, mean improvement 30.9%). The program also led to significant improvements in EQ5D-5L Index scores at week 6 (0.54 (SD 0.25) vs. 0.44 (SD 0.23) p=0.0005, mean improvement 25.0%); week 10 (0.51 (SD 0.25) vs. 0.44 (SD 0.24), p=0.0382, mean improvement 15.9%); and week 22 (0.54 (SD 0.23) vs. 0.46 (SD 0.23), p=0.0103, mean improvement 17.4%. The program was well received with 100% engagement and completion at 6 weeks. NPS scores showed 70% of participants were promoters of the program with a mean individual score of 8.64. CONCLUSIONS The pilot study indicates that the Avid platform is safe, feasible and effective. It produces significant and sustained improvements in the symptoms and severity of long COVID, and wider measures of quality of life in the short-term. These findings suggest that the approach may provide a clinically impactful, cost-effective, and scalable platform that can successfully manage the challenges of long COVID. The modular approach of the platform also readily facilitates its rapid development and expansion to address other health challenges and long-term conditions in the future.